SEC Filings

Form Description Filing date View
3

Initial filing by director officer or owner of more than ten percent.

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML
S-3ASR

S-3ASR

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML
10-Q

Quarterly report which provides a continuing view of a company's financial position

View HTML EX-101.INS - XBRL INSTANCE DOCUMENT
SC 13G

A statement of beneficial ownership of common stock by certain persons

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML
10-Q

Quarterly report which provides a continuing view of a company's financial position

View HTML EX-101.INS - XBRL INSTANCE DOCUMENT

About us

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

 

Our Pipeline